Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815434 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| SCHEMBL7330612 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| SCHEMBL5815432 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| SCHEMBL7330624 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| Hydrochloric Acid SCHEMBL11694448 | 0.98 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| Hydrochloric Acid SCHEMBL11694454 | 0.98 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| Hydrochloric Acid SCHEMBL11695457 | 0.98 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| Hydrochloric Acid SCHEMBL11695440 | 0.98 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3SIGMAR1KDM1A | |
| SCHEMBL4367085 | 0.85 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6924410 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035105-A1 | Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2002-03-21 | — | — | US | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-4045488-A | ANTIDEPRESSANTS OR PSYCHOMOTOR STIMULANTS | PFIZER INC. (US) | 1977-08-30 | — | — | US | claimed |
| US-4029731-A | TREATING DEPRESSION | PFIZER INC. (US) | 1977-06-14 | — | — | US | claimed |
| JP-7173056-A | — | — | None | — | — | JP | disclosed |
| JP-7173056-A | — | — | None | — | — | JP | disclosed |
| EP-3712128-A1 | PHOTOCHEMICAL INTERMOLECULAR AMINATION METHOD | Fundació Institut Català d'Investigació Química (ICIQ) (ES) | 2020-09-23 | — | — | EP | disclosed |
| EP-1542961-B1 | TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE FOR USE IN TREATMENT OF CNS DISORDERS | SEPRACOR INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-7772437-B2 | Process of making sertraline form II | HETERO DRUGS LIMITED (IN) | 2010-08-10 | — | — | US | disclosed |
| US-7772438-B2 | Process of making sertraline form I | HETERO DRUGS LIMITED (IN) | 2010-08-10 | — | — | US | disclosed |
| US-20090177010-A1 | PROCESS OF MAKING SERTRALINE FORM I | HETERO DRUGS LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
| US-4045488-A | ANTIDEPRESSANTS OR PSYCHOMOTOR STIMULANTS | PFIZER INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4045488-A | ANTIDEPRESSANTS OR PSYCHOMOTOR STIMULANTS | PFIZER INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4029731-A | TREATING DEPRESSION | PFIZER INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4029731-A | TREATING DEPRESSION | PFIZER INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090177010-A1 | PROCESS OF MAKING SERTRALINE FORM I | HTR5A, HTR2A, HTR2C | SLC6A2 22/4885SLC6A4 6/4885SLC6A3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.